Niagen Bioscience (NAGE) shared results from a clinical study published in the peer-reviewed journal Aging Cell. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience’s patented nicotinamide riboside ingredient, Niagen, in individuals with Werner syndrome, a rare genetic disorder marked by rapid aging and premature mortality. The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience price target raised to $23 from $10 at Roth Capital
- Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’
- Niagen Bioscience initiated with a Buy at Canaccord
- Niagen Biosciences Reports Strong Q1 2025 Growth
- Niagen Bioscience’s Clinical Expansion and Strong Financial Performance Drive Buy Rating